AI

Gaxos Health forms Medical Advisory Board

Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that its health and wellness division, Gaxos Health, has formed a medical advisory board for providing invaluable insight into product development and creating strategic opportunities. The Company has appointed Dr. Nate Lebowitz, M.D. as the Chairman of the Advisory Board.

“The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI. “An advisory board of experts in medicine will be instrumental in guiding us through the process of offering the best product and advancing our mission of creating value for shareholders.”

Dr. Nate Lebowitz, MD, is a leading cardiologist at Hackensack University Medical Center in New Jersey. He is an attending cardiologist at Hackensack University Medical Center’s Heart and Vascular Hospital where he is director of lipids and preventive cardiology. He is also an attending cardiologist at Englewood Hospital and Medical Center. Dr. Lebowitz received his MD from Cornell University Medical College (now Weill-Cornell Medical College) in New York. He completed his residency in internal medicine at Yale – New Haven Hospital in New Haven, Connecticut, and a fellowship in cardiology at the New York Hospital – Cornell Medical Center in New York, New York. He is board certified in cardiology.

Dr Lebowitz is a fellow of the American College of Cardiology. He is a diplomate of the American Society of Nuclear Cardiology (ASNC), and a member of the National Lipid Association and the American Society of Nuclear Cardiology He is also a founding member of the Society for the Advancement of Blood Management and co-founder of the ASNC New Jersey Working Group.

Dr Lebowitz’s clinical and research interests include plaque morphology in vascular biology, genetic dyslipidemias, obesity, nutrition and cardiometabolic disorders.  He has authored or coauthored articles published in peer-reviewed journals such as the Journal of the American College of Cardiology and the Annals of Thoracic Surgery. He is principal investigator in multicenter clinical trials.

“We welcome Dr. Lebowitz to the advisory board as his experience and talents will be invaluable to the creation of our solution,” Vadim Mats added. “We look forward to leveraging his insights and expertise.”

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Genesis Therapeutics closes Oversubscribed $200 Million Series B

Business Wire

Everymind secures #1 Salesforce Partner Status

PR Newswire

Zest AI Doubles Down On Credit Union Market For AI Underwriting

PR Newswire